Lung Cancer Trial, Recruiting NCT06934343 Sponsor: University of Utah Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06934343
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who were diagnosed with advanced non-small cell lung cancer (a type of lung cancer) between January 1, 2011, and June 30, 2024.
  • People whose medical records can be followed up until at least December 31, 2024, with at least six months of information available after diagnosis.

Who may not be able to join:

  • People who have less than one full day of medical follow-up recorded after starting their first round of treatment.
  • People whose cancer has a specific genetic change (mutation) in any of the following genes: ALK, BRAF, EGFR, KRAS, or ROS1.
  • People whose cancer tested below 50% for a protein called PD-L1 — this trial focuses on cases where PD-L1 levels were 50% or higher (confirm with trial site).
  • People whose first treatment was anything other than immunotherapy or a combination of chemotherapy and immunotherapy — other treatment types are not included in this trial (confirm with trial site).
  • People who have already received a second round of treatment for their cancer, including those who took part in another clinical trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 September 2024
Est. completion
31 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov